Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets
Development Costs Are Currently Too High For Smaller-Value Biologics To Be Viable
Executive Summary
A more streamlined European regulatory pathway for biosimilars – potentially removing the requirement for confirmatory efficacy trials – is needed for the industry to be able to feasibly offer competition to smaller-value biologic brands, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference.
You may also be interested in...
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
Generics Bulletin Editor’s Picks For Q4 2022
Looking back over the fourth quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from October to December that include a leadership change for one of the top industry players, some key developments for biosimilars and the announcement of the winners of our annual awards.